Navigation Links
Innolife Pharma Provides Initial Update on Negotiations for Significant Product Joint Venture
Date:5/12/2008

MARKHAM, ON, May 12 /PRNewswire-FirstCall/ - Innolife Pharma, Inc. (Other OTC:INNP.PK - News) has been in discussion over the previous eight months regarding the formation of a joint venture partnership. INNP has reached a point in these negotiations where final written terms have been submitted on all key issues which could lead to the Company's very first product acquisition. It should be noted that this process evolved methodically over this extended period due to the successful, long term history of the product involved, and the well-established reputation of its founding corporation.

Management anticipates additional forthcoming news and progress updates on the closing of this transaction that can complete great strides in two specific areas. One is the awarding of valuable rights to Innolife Pharma of an industry leading product. This established brand known for innovation and consistency over more than two decades can be launched in a brand new target market for the first time representing the largest market of this type on a global scale. Secondly, but of equal importance, is the solidifying of a joint venture with a partner of great quality and experience. The intention is to unite the market access and distribution capabilities of INNP with the knowledge, leadership, and existing contacts of our potential joint venture partner.

INNP will continue to reveal details of our aggressive strategy geared towards long term growth as they become available. We are confident that a partnership will emerge and start to bring in revenue in the near term based on the high level of negotiations reached with an industry leader in the information technology field. The Company believes that the size of our target market is potentially in excess of US$20 Billion. Updates will also be available on the Company's official corporate web site at http://www.innolifepharma.com. Please bear with us as the site is still under development, but will be officially launched upon finalization of our partnership and product acquisition.

FORWARD-LOOKING STATEMENTS:

This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the Company.


'/>"/>
SOURCE Innolife Pharma Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Alseres Pharmaceuticals to Host 2008 First Quarter Conference Call
2. Shengtai Pharmaceutical, Inc. Announces Conference Call to Discuss Third Quarter Results of Fiscal Year 2008
3. Par Pharmaceutical Reports First Quarter 2008 Results
4. IDM Pharma Reports First Quarter Financial Results
5. Vion Pharmaceuticals to Appeal Nasdaq Delisting
6. Amneal Pharmaceuticals Receives US FDA Approval for Three Generic Prescription Drugs; Two Using New FDA Electronic Filing Format
7. Patients, Doctors, Pharmacists Praise Bipartisan House Resolution on Compounded Hormones Containing Estriol
8. AMDL Signs Letter of Intent to Purchase a China Based Pharmaceutical Distribution Company
9. Par Pharmaceutical Acquires Spectrum Pharmaceuticals Interest In Sumatriptan Injection
10. ISTA Pharmaceuticals to Present at the Bank of America 2008 Health Care Conference
11. WuXi PharmaTech Announces Postponement of Proposed Follow-on Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... IN (PRWEB) , ... February 10, 2016 , ... ... benefits advisory organization, welcomes S.S. Nesbitt as the latest addition to its growing ... has seven other locations throughout the Southeast, from Orlando to Huntsville and in ...
(Date:2/10/2016)... ... ... Armune BioScience signed a definitive agreement with ARCpoint Labs ... the country. Launched in April of 2015, Apifiny is the only cancer specific, non-PSA ... volume exceeded 3,000 tests in 2015. Primary care physicians and urologists have utilized Apifiny ...
(Date:2/10/2016)... ... February 10, 2016 , ... For additional information contact ... , Pioneering book "Better with Age: The Ultimate Guide to Brain Training" by award-winning ... improve memory. The book’s publication date is March 16, 2016. A free review ...
(Date:2/10/2016)... ... February 10, 2016 , ... Everseat has joined the award-winning ... to physicians. The integration will enable Allscripts users to post open appointments to ... mobile app. , The partnership gives Everseat substantial added power to help Allscripts ...
(Date:2/10/2016)... ... ... Workrite Ergonomics this week announced the launch of the Conform Monitor Arm Series, ... was to develop a product from the ground up that would provide the most ... Hulsey, Product Manager for Workrite Ergonomics. “The Conform series features a wide variety ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... BASEL, Switzerland and SAN DIEGO ... Houston , Inc., a global leader in viral gene ... gene therapy treatments for congestive heart failure and other ... to develop a scalable manufacturing process and produce cGMP-grade ... clinical trials. --> ...
(Date:2/10/2016)... Immune Pharmaceuticals Inc. (NASDAQ: IMNP ), ... has filed a patent application directed to the treatment ... --> --> The new invention ... (histamine dihydrochloride) in combination with immune checkpoint inhibitors. The ... of Ceplene and IL-2 therapy in patients with Acute ...
(Date:2/10/2016)... ANGELES , Feb. 10, 2016  Oxis International ... cancer drug, OXS-1550, was described as a "clinical trial ... the drug went into complete cancer remission. ... University of Minnesota Masonic Cancer Center. --> ... University of Minnesota Masonic Cancer Center. --> ...
Breaking Medicine Technology: